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Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence, accounting for approximately 7% of
childhood cancers. Current therapies include nonspeciﬁc cytotoxic chemotherapy regimens, radiation therapy, and surgery; how-
ever, these multimodality strategies are unsuccessful in the majority of patients with high-risk disease. It is generally believed that
these tumors represent arrested or aberrant skeletal muscle development, and, accordingly, developmental signaling pathways cri-
tical to myogenesis such as Notch, WNT, and Hedgehog may represent new therapeutic targets. In this paper, we summarize the
current preclinical studies linking these embryonic pathways to rhabdomyosarcoma tumorigenesis and provide support for the
investigation of targeted therapies in this embryonic cancer.
1.Introduction
Rhabdomyosarcoma (RMS) is the most common soft tissue
sarcoma of childhood and adolescence, accounting for ap-
proximately 7% of all pediatric cancers [1, 2]. Tumors are
classiﬁed based on their histology as embryonal (∼60%),
alveolar (∼20%), or other (∼20%) subtypes. Embryonal
(eRMS) and alveolar (aRMS) subtypes have unique genetics,
patterns of involvement, biology, and prognosis. Approxi-
mately 80% of aRMSs contain a stable reciprocal transloca-
tion involving either the PAX3 or PAX7 transcription factors
with the FOXO1 transcription factor, resulting in a fusion
gene with altered transcriptional and translational proper-
ties, while 80% of eRMSs have loss of heterozygosity in chro-
mosome 11p15 [1, 3]. aRMS more commonly occurs in the
extremities and has a high predilection for metastasis, while
eRMS is more likely to present as localized disease in the
genitourinaryorhead/neckregions.PatientswithaRMShave
an inferior survival rate compared to embryonal subtype,
even when controlled for risk groups, with eRMS and aRMS
having ﬁve-year OS of 80% and 52%, respectively, [4]. In
addition to histologic subtype, patients are risk-stratiﬁed
based on pretreatment stage and clinical group. Currently,
the Children’s Oncology Group (COG) Soft Tissue Sarcoma
committee (formerly Intergroup Rhabdomyosarcoma Study
Group (IRSG)) classiﬁesand treats patients according to low,
intermediate, and high risk prognostic groups.
ThecurrenttreatmentstrategiesforRMSincludechemo-
therapy, radiation, and surgery. Over the last 50 years, the
survival rates for patients with low- and intermediate-risk
disease have improved signiﬁcantly due to risk stratiﬁcation,
combination chemotherapy regimens, and cooperative clini-
cal trials [1]. The IRSG was formed in 1972 and perfor-
med ﬁve successive clinical trials over the next 25 years. Sub-
sequently, the Soft Tissue Sarcoma (STS) committee of the
COG has continued to conduct clinical trials for RMS.
During this time, the survival rates for patients with low-
and intermediate-risk disease improved signiﬁcantly from2 Sarcoma
a ∼25% OS to the most recent studies with mature data for
low-risk (IRSG IV) and intermediate-risk RMS (D9803)
demonstrating a ﬁve-year FFS of 90% and four-year OS of
71%, respectively, [5, 6]. Similarly, multiple international co-
operative groups including the Italian Group, International
Society of Pediatric Oncology (SIOP), CWS, and European
Intergroup have demonstrated improvements in the survival
forpatientswithlocalizeddisease[7].Unfortunately,thesur-
vival rate for patients with high-risk disease has not similarly
improvedabovethedismal20–30%rate[7].Themostrecent
mature study of patients with high-risk RMS enrolled in
COG studies (IRS IV) reported a three-year OS of 5% for
the highest-risk group (>three metastatic sites, unfavorable
histology) [8]. In addition, two consecutive European Inter-
group Studies of childhood metastatic RMS (MMT4-89 and
MMT4-91) also demonstrated persistently poor outcomes
with a ﬁve-year overall survival rate of 24% [9]. Finally,
patients with refractory and relapsed disease continue to do
very poorly with an OS of 10% at ﬁve years [10]. Recent
eﬀorts to improve this poor prognosis in high-risk patients
haveincludedmultiagent,intervalcompressedtherapy,high-
dose chemotherapy with stem cell rescue, oral maintenance
regimens, and novel targeted therapies including growth
factor inhibition and regulation of angiogenesis. While these
current studies oﬀer hope for improved cure rates in high-
risk RMS, there remains a great need for new therapies tar-
getingthemolecularpathwaysthatareinvolvedinthepatho-
genesis of RMS. We believe that strategies aimed at reducing
theregenerativepotentialoftumorsbyinhibitingtheembry-
onic pathways critical to tumor initiation and maintenance
will be important for future investigation.
RMS is believed to arise from skeletal muscle precursors
that fail to undergo appropriate terminal diﬀerentiation.
Although the precise cell of origin is unclear, skeletal muscle
precursors are obvious suspects because they already possess
“stemness” characteristics—features that are shared with
cancercells—suchasself-renewal,highratesofproliferation,
resistance to senescence, and reversal of quiescence. In addi-
tion to these stem cell properties, skeletal muscle precursors
share stemness markers with RMS cancer cells including
PAX3, PAX7, MET, and myogenic regulatory factors [11, 12].
Inthisscenario,asinglesomaticmutationthatblocksthedif-
ferentiationcapacityofmuscleprecursorsmightbesuﬃcient
to cause malignant transformation. Alternatively, such a mu-
tation may arrest normal diﬀerentiation and thus expand the
number of muscle precursors “at risk” for additional trans-
forming events. Finally, inappropriate embryonic cell signal-
ing after cells have previously diﬀerentiated beyond a stem
cell fate may reactivate the molecular mechanisms necessary
for dediﬀerentiation phenotypes and stemness behaviors, re-
sulting in tumorigenesis [13]. In skeletal muscle, the Notch,
WNT, and Hedgehog signaling pathways regulate self-ren-
ewal versus diﬀerentiation fates of muscle stem cells and thus
control the balance of proliferation versus diﬀerentiation.
These embryonic signaling pathways that are responsible for
normal skeletal muscle diﬀerentiation may therefore play
a critical role in RMS tumorigenesis by stabilizing muscle
precursor cells and allowing more opportunities for secon-
dary, cooperating mutations to occur, by directly inhibiting
normal diﬀerentiation leading to transformation or by pro-
moting dediﬀerentiation of mature muscle cells. In this
paper, we review the physiologic role of several of these
embryonic signaling pathways including Notch, WNT, and
Hedgehog in myogenesis as well as the preclinical data that
supports their role in RMS tumorigenesis.
2.SkeletalMyogenesis
Myogenesis is a complex and carefully timed process that
results in discrete muscle groups that are fully functional
even shortly after birth. In mammals, skeletal myogenesis
begins during embryonic life and proceeds through fetal,
neonatal, and adult developmental stages [14]. There are
three ways in which embryonic myogenesis can be described:
developmental stage, phase of myogenesis, or type of myo-
blast [14–16]. Fortunately, these diﬀerent ways of describing
myogenesis parallel each other except for the neonatal devel-
opmental stage as there is no known myoblast unique to it
[14]. Myogenesis is initiated when the presomitic paraxial
mesoderm contracts to form somites, which then diﬀeren-
tiate into the dermomyotome and the sclerotome [17]. The
epaxial and hypaxial myotomes are formed from the dermo-
myotome,thesourceofalltrunkandlimbmuscles.Cellsthat
will form muscle in the limbs undergo an epithelial to mes-
enchymal transition, delaminate from the dermomyotomes,
and migrate to their ﬁnal tissue locations [17]. During em-
bryonic myogenesis, or the ﬁrst myogenic phase, the primary
myotome is developed and the basic muscle pattern estab-
lished. In the limb, this occurs between E10.5 and E12.5 in
mice [14, 15]. Both fetal myogenesis (in the limb, E14.5-P)
and neonatal (P0-21) myogenesis are encompassed by the
second myogenic phase, which generates the adult muscu-
lature and allows for growth and development of muscle.
Finally, adult myogenesis (after P21) occurs through the use
of satellite cells and is responsible for postnatal growth and
repair. Further detailed information about myogenesis can
be found in [14–17].
2.1. Embryonic Signaling Pathways and Skeletal Myogenesis.
Embryonic signaling pathways including Notch, WNT, and
Hedgehog play a critical role in the transition of muscle pre-
cursors from self-renewal to diﬀerentiation fates during both
muscle development and postnatal muscle regeneration.
During muscle development and postnatal muscle regenera-
tion, mononucleated progenitor cells undergo ampliﬁcation
and asymmetric diﬀerentiation along a myogenic lineage to
form multinucleated myotubes and ultimately myoﬁbers,
which are the terminally diﬀerentiated unit of skeletal mus-
cle. In both fetal and postnatal development, there remains
a small population of mononuclear muscle stem cells (fetal)
or satellite cells (postnatal) that remain undiﬀerentiated and
retain the ability to proliferate and diﬀerentiate in response
to growth signals or tissue damage. In normal myogenesis,
the Notch, WNT, and Hedgehog signaling pathways have
been shown to regulate the progression of muscle stem cells
towardslineage-committedprogenitors,and,therefore,these
embryonic signaling pathways function to preserve andSarcoma 3
Table 1: Embryonic signaling pathways in rhabdomyosarcoma.
Embryonic pathway Mechanism Reference
Notch
( i )P r o m o t e sp r o l i f e r a t i o n ,s u p p r e s s e sd i ﬀerentiation, and avoids irreversible cell
cycle arrest [18]
(ii) Promotes invasiveness and mobility [19]
(iii) Promotes proliferation and suppresses diﬀerentiation [20]
WNT ( i )S u p p r e s s e sd i ﬀerentiation and resists apoptosis [21]
(ii) Promotes proliferation and resists apoptosis [22]
Hedgehog ( i )P r o m o t e sp r o l i f e r a t i o n [ 23]
(ii) Suppresses diﬀerentiation [24]
expand this subpopulation of muscle stem cells. Given the
critical role of these pathways in myogenesis, aberrant exp-
ression, activation, or regulation of these pathways may be
involved in RMS tumorigenesis and may present novel ther-
apeutic targets in the treatment of RMS. Speciﬁcally, RMS
may exploit the function of these pathways in order to allow
forpersistentstemcellmaintenance,self-renewal,andtumor
initiation (Table 1).
2.2. Notch Pathways. The Notch signaling pathway is an evo-
lutionarily conserved signaling pathway that mediates many
tissue progenitor cell fate decisions including the determina-
tion between self-renewal and diﬀerentiation. This pathway
includes multiple transmembrane receptors and ligands that
function through direct cell surface contact. In mammals,
there are four Notch receptors (Notch1–4) and ﬁve Notch
ligands(Jagged1,2andDLL1,3,4).Signalingisinitiatedwhen
neighboring cells come into direct contact resulting in
ligand-receptor binding. Activation of the receptor by ligand
binding is followed by a two-step proteolytic cleavage of the
cytoplasmicportionofthereceptorandreleaseofthecleaved
active Notch receptor (intracellular Notch, ICN). ICN then
translocates to the nucleus where it binds to the transcrip-
tionfactorRBP-JincooperationwiththecoactivatorMaster-
mind, resulting in a large transcriptional activation complex
that promotes the transcription of target genes (Figure 1). In
musclestemcells,Notchregulatesthebalancebetweenmain-
tenance of progenitor cells by inhibition of diﬀerentiation
versus the facilitation of commitment to muscle lineage.
Notch signaling maintains muscle progenitors during
bothembryogenesisandpostnataldevelopmentbysuppress-
ing myogenic diﬀerentiation. Studies in the 1990s demon-
strated that overexpression of ICN in murine myoblasts in-
hibits their diﬀerentiation [25], with subsequent studies
demonstrating multiple mechanisms for this diﬀerentiation
block. Kuroda et al. demonstrated that activation of the
Notch signaling pathway via overexpression of Notch ligands
results in inhibition of muscle regulatory factors including
MyoDinmousemyoblasts[26].Inaddition,activationofthe
Notch pathway reduces the transcription of the promyogenic
genes myogenin and MEF2c by the Notch target gene Hey1
[27], and, furthermore, ICN directly inhibits the transcrip-
tional activity of MEF2c [28].
In addition to inhibition of diﬀerentiation, Notch sig-
naling promotes the renewal of stem cells during embryo-
genesis and satellite cells during postnatal myogenesis. Over-
expression of activated Notch (ICN) in myoblasts results in
proliferation of satellite cells and inhibition of diﬀerentia-
tion into fusion-competent myoblasts [29]. In agreement
with these results, Notch signaling loss-of-function studies
have demonstrated inappropriate myogenic diﬀerentiation
in muscle progenitors. While there is redundancy in the
Notch ligands and receptors, the transcription factor RBP-J
is the central nuclear mediator of Notch signaling. Using a
conditional knockout of RBP-J in mouse muscle precursor
cells, Vasyutina et al. showed that inactivation of the Notch
pathway results in inappropriate diﬀerentiation of myogenic
cells and depletion of muscle progenitor cells during emb-
ryogenesis [30]. Similarly, in postnatal muscle repair follow-
ing injury, inhibition of the Notch pathway reduces the abil-
ity of satellite cells to regenerate muscle [29]. In conclusion,
the Notch signaling pathway promotes muscle stem cell
maintenance by inhibiting early diﬀerentiation and expand-
ing pools of progenitor cells during both embryogenesis and
postnatalmuscleregeneration;however,itdoesnotappearto
be involved in the direction of terminally diﬀerentiated cells.
2.3. Wnt Pathway. Similar to Notch, the WNT signaling
pathway is conserved in all animals, including worms, ﬂies,
and mammals [31]. In mammals, Wnt signaling is divided
into a number of pathways, including the canonical/β-cate-
nin, the noncanonical planar cell polarity (PCP), and the
Wnt/Ca2+ pathways [32]. Of these, the canonical/β-catenin
pathway is the best understood. In the absence of Wnt, the
pathway is inactive, allowing for the phosphorylation of β-
cateninbyglycogensynthasekinase3(GSK3)andcaseinkin-
ase 1 (CK1). These two kinases along with scaﬀolding pro-
teins Axin and adenomatous polyposis coli gene product
(APC) form the destruction complex. Once β-catenin is
phosphorylated, it is recognized and targeted for proteaso-
maldegradationbyβ-Trcp,anE3ubiquitinligase[31].Alter-
natively, in the presence of Wnt, the pathway is active. Wnt
binds the extracellular region of Frizzled (Fzd) and its core-
ceptor low-density lipoprotein receptor-related protein 6
(LRP6) or LRP5. The formation of a Wnt-Fzd-LRP complex
recruits Dishevelled (Dsh) and results in the recruitment of
Axin and the rest of the destruction complex. This leads to4 Sarcoma
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Figure 1: Overview of the Notch pathway. The pathway is active when a Notch ligand, such as Delta or Jagged, binds to a Notch receptor on
a neighboring cell. Notch is cleaved and the cytoplasmic portion (ICN) translocates to the nucleus where it binds RBP-J in cooperation with
Mastermind (MAML) to activate transcription of target genes.
inhibition of the destruction complex, allowing for stabiliza-
tion of β-catenin, which accumulates in the cytoplasm and
translocate to the nucleus where it forms complexes with
TCF/LEF and activates Wnt target genes (Figure 2)[ 31].
Inhibitors of the Wnt pathway include the secreted frizzled-
related protein (SFRP) family and Wnt inhibitory proteins
(WIF),whichinhibitWntdirectlyviadirectbinding,andthe
Dickkopf (DKK) family, which inhibit LRPs [31].
Duringskeletalmyogenesis,Wnthasvariousrolesinem-
bryonic,fetal,andneonatalmyogenesis.Attheonsetofemb-
ryonic myogenesis, MyoD is activated in the presomitic
mesoderm by Wnt7a signaling through a β-catenin indepen-
dent pathway [33]. In contrast, Myf5 expression in somites
is dependent on β-catenin signaling, and expression of β-
catenin is suﬃcient to induce Myf5 expression in the somites
[34]. Interestingly, in the presomitic mesoderm, both β-cate-
nin signaling and sonic hedgehog/Gli signaling are required
for Myf5 expression [34]. Further, Wnt1 preferentially acti-
vates Myf5, and Wnt7a preferentially activates MyoD in the
presomitic mesoderm; however, Wnt4, Wnt5a, and Wnt6
can moderately activate both MyoD and Myf5 expression
[35]. During embryonic myogenesis, β-catenin is required
for dermomyotome and myotome formation, but not requi-
red for embryonic axial myogenesis [36]. Fetal myogenesis,
consistent with having diﬀerent myogenic progenitors than
embryonic myogenesis, has diﬀerent requirements for β-
catenin. In contrast to embryonic myogenesis, β-catenin is
important for fetal limb myogenesis, particularly the forma-
tion of slow ﬁbers. Further, β-catenin positively regulates the
number of Pax7+ myogenic progenitors [36].
In adult myogenesis, the role of the Wnt pathway and β-
catenin is unclear, as some data demonstrate that activated
β-catenin promotes myogenic lineage progression and dif-
ferentiation,whileotherstudiesﬁndthatitpromotessatellite
cell proliferation and inhibits diﬀerentiation. In regenerating
muscle, activating or inhibiting the Wnt pathway early (two
days) following injury did not alter myogenesis; however,
activating the Wnt pathway late (four days) following injury
increased myogenic diﬀerentiation [37]. Further, a transition
fromNotchtoWntsignalingisimportantfortheprogressing
along the myogenic lineage from quiescent satellite cell to
fully diﬀerentiated muscle [37]. In CD45+ stem cells, acti-
vationoftheWntpathwayallowsthesecellstoenterthemyo-
genic lineage and undergo myogenic diﬀerentiation [38].
This myogenic diﬀerentiation can by blocked by inhibition
of the Wnt pathway using SFRPs in satellite cells and CD45+
stem cells [37–39]. Interestingly, increased Wnt signaling in
the myogenic progenitor cells of aged mice (∼24 months)
leads to their conversion from a myogenic to ﬁbrogenic line-
age and contribute to tissue ﬁbrosis [40]. Finally, growth of
muscle (hypertrophy) following muscle overload appears to
require β-catenin expression [41].
In contrast, β-catenin increased proliferation of Pax7+
satellite cells and inhibited their diﬀerentiation in both an in
vitro and an in vivo setting [42, 43]. Further, demonstrating
the complexity of this pathway in regulating myogenesis,
only Wnt1, Wnt3a, and Wnt5a promoted satellite cell prolif-
eration, while Wnt4 and Wnt6 were inhibitory [42]. Finally,
during muscle regeneration Wnt1, Wnt3a, Wnt7a, and
Wnt11, the Wnts often associated with embryonic myoge-
nesis, are not induced, but SFPR1, SFRP2, and SFRP3, anta-
gonists of the Wnt pathway, are induced, suggesting a down-
regulation of the pathway [44]. Future research should aim
to reconcile these two seemingly opposite roles of the Wnt
pathway and β-catenin in myogenic diﬀerentiation.
2.4. Hedgehog Pathway. The Hedgehog signaling pathway
has been rightly described as an enigmatic developmental
pathway in metazoans, due in part to an incomplete under-
standing of how the pathway constituent proteins inter-
act [45]. Currently, it is clear that the Hedgehog signaling
cascade is initiated when a Hedgehog protein, such as
Sonic Hedgehog (SHH), Desert Hedgehog (DHH), or India
Hedgehog (IHH) is translatedand subsequentlyautocleaved,
forming both amino-terminal and carboxyl-terminal pep-
tides [46]. The amino-terminal peptide is then transported
through the plasma membrane of the signaling cell via theSarcoma 5
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Figure 2: Overview of the canonical Wnt pathway. In the inactive state, Wnt is absent and β-catenin is phosphorylated by the destruction
complex, leading to its degradation. In the active state, Wnt binds Frizzled (Fzd) and LRP. Dishevelled (Dsh) and axin are recruited to the
Wnt-Fzd-LRP complex, which inhibits the destruction complex. β-catenin is no longer phosphorylated and can translocate to the nucleus to
activate transcription of target genes.
multipass transmembrane protein Dispatched and diﬀuses
across the extracellular space in a signaling gradient [47].
In Drosophila melanogaster, Hedgehog signaling is medi-
ated by the transcription factor Cubitus interruptus (Ci). In
contrast, the mammalian ortholog to Ci is comprised of the
three GLI family members GLI1, GLI2, and GLI3. Under
homeostaticconditions,cellswiththepotentialtorespondto
Hedgehog signaling (including the signaling cell) express the
cellsurfacereceptorPatched1(PTCH1),whichconstitutively
inhibits the membrane protein Smoothened (SMO) [48].
When a Hedgehog ligand binds PTCH1, PTCH1 inhibition
of SMO is prevented by a mechanism that remains to be fully
characterized and SMO is able to accumulate at the base of
the primary cilium (in mammals) [49]. SMO localization to
the base of the primary cilium leads to the stabilization of
cytoplasmic GLI1/2 and degradation of the repressor GLI3,
allowing GLI1/2 to translocate to the nucleus and activate
downstream targets of Hedgehog signaling such as HHIP,
PTCH1, GLI1, and GLI2 (Figure 3)[ 50].
Similar to the Notch and Wnt pathways, the Hedgehog
pathway has been shown to play a crucial role in the regu-
lation of early myogenesis in vertebrates. Hedgehog ligand
diﬀuses from cells within the notochord and ventral neural
tube into the developing somites where Hedgehog signaling
is required to maintain MYF5 expression in the dorsomedial
lip of the dermomyotome [51]. During embryonic and fetal
myogenesis, Hedgehog is required for survival, proliferation,
and maintenance of myogenic regulatory factors (MRFs) in
developingmyoblastsandmyotubesinbothepaxialandhyp-
axial muscles, although it is dispensable for the initiation of
myogenesis in the hypaxial limb of the mouse [52]. Because
Hedgehog signaling plays an important role in survival and
proliferation in the developing myotome, it is not surprising
that it is indispensable for adult skeletal muscle myogenesis.
Although postnatal skeletal muscle is largely quiescent,
thesatellitecellhasaregenerativecapacityakintohighlypro-
liferative stem cell populations such as the hematopoietic
stem cell. Recent data suggests that Hedgehog signaling plays
a unique role in adult myogenesis because inhibition of Shh
via cyclopamine impaired the activation of Myf5 and MyoD
in skeletal muscle progenitors and led to a reduction in the
number of activated satellite cells and myoblasts following
injury in vivo. Furthermore, the addition of Shh to C2C12
myoblasts in vitro led to an increase in proliferation [53].
In addition, the pathway has been shown to block the diﬀe-
rentiation of myogenic precursor cells into myotubes and
maintain satellite cells as self-renewing precursors [54]. This
group also demonstrated that Hedgehog signaling inhibits
apoptosis in muscle precursors. Other studies have con-
cluded that Hedgehog signaling represses terminal diﬀeren-
tiation of myoblasts [55]. Although the role of the Hedgehog
pathway in satellite cell biology is in its infancy, it is be-
comingincreasinglyclearthatHedgehogplaysarolenotonly
in activation of satellite cells, but in the proliferation of
myoblasts and the process of terminal skeletal muscle diﬀer-
entiation.
2.5. Cross-Talk between the Notch, Wnt, and Hedgehog Path-
ways. TheabilityofNotchsignalingtomaintainmusclestem
cellsinbothfetalandadultmusclelikelyrequirestheinputof
the Wnt and Hedgehog signaling pathways important in tis-
sue diﬀerentiation and stem cell biology. Brack et al. demon-
strated that coordinated transition from Notch activation to
WNT activation is required to promote myogenic lineage6 Sarcoma
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Figure 3: Overview of the Hedgehog pathway. In the inactive state, Patched 1 (PTCH1) inhibits Smoothened (SMO) and Gli is targeted for
degradation by the proteasome. In the active state, Hedgehog (HH) is translated, cleaved, and transported by Dispatched to the extracellular
space. HH is able to bind to PTCH1, which prevents inhibition of SMO and allows it to accumulate at base of the primary cilium. Gli is then
stabilized and translocates to the nucleus to activate transcription of target genes.
progression from satellite cells to fusion-competent myo-
blasts [37]. They additionally show that in skeletal muscle
precursors, aberrant activation of Notch signaling or inac-
tivation of WNT signaling prevents myogenic lineage pro-
gression [29, 37]. Thus, progression of skeletal muscle stem
cells along a myogenic lineage is controlled by early Notch
activation and late WNT activation, and the coordinated
transition from Notch activation to WNT activation dictates
myogenic lineage progression from muscle stem cells to dif-
ferentiated myogenic progenitors. Though not well studied
in mesenchymal tissues, the interaction between the Wnt
and Hedgehog pathways can be mediated through GSK3β.
Brieﬂy, it has been demonstrated in epithelium that loss of
Shh in the hair follicle leads to an increase in GSK3β, sug-
gesting that activated Hedgehog signaling can, given the
appropriate cellular context, potentiate Wnt signaling acti-
vation via β-catenin stabilization [56]. These studies demon-
strate that the cumulative eﬀect of Notch, WNT, and Hedge-
hog signaling pathways regulates the progression from mus-
cle progenitor expansion to diﬀerentiation phenotypes and
ultimately contribute to inhibit embryonal myogenesis.
3. Rhabdomyosarcomagenesis
Traditionally the study of RMS tumorigenesis has focused on
genes and proteins that have been found to be dysregulated
in human, and later murine models of RMS cell lines and
tissues. Thus, there has been intense focus, rightly so, on the
classictumorsuppressorsRbandp53,classiconcogenessuch
as Ras and Myc, a variety of receptor tyrosine kinases such as
IGF1R, cMET, and of course the aRMS-speciﬁc chromoso-
mal translocations. As such, newer treatment agents that can
target these moieties, such as the anti-IGF1R monoclonals
and small-molecule RTK inhibitors, have made their way
through preclinical studies and are being tested in human
clinical trials. However, recently there have been developed
classes of drugs that can inhibit the Notch, Wnt, and
Hedgehog pathways, and this has likely spurred a renewed
interest in understanding the biology of these pathways in
RMS.
3.1. Notch and Rhabdomyosarcoma. The ﬁrst study linking
the Notch signaling pathway to RMS investigated the inﬂu-
ence of Hes1, a Notch target gene, on reversibility of cellular
quiescence. In this work, Sang et al. demonstrated that HES1
mRNA expression was increased in 21 primary RMS tumors
and three RMS cell lines (one eRMS and two aRMS) [18].
TheythenusedadnHes1constructtoevaluatetheroleofthis
gene on RMS diﬀerentiation. Speciﬁcally, they transduced an
aRMS cell line, RHJT, with either dnHes1 or empty vector
control. RMS cells expressing dnHes1 demonstrated early
diﬀerentiation and inhibited proliferation. Similarly, treat-
ment of RHJT cells with the pharmacologic Notch inhibitor
DAPT also promoted diﬀerentiation. From these experi-
ments, they concluded that the transcription factor Hes1,
via Notch-dependent signaling pathway, contributes to the
initiationandprogressionofRMSbysuppressingirreversible
s t a t e ss u c ha sd i ﬀerentiation and senescence.
A subsequent study by Roma et al. evaluated the con-
tribution of the Notch signaling pathway to RMS mobility
and invasiveness [19]. Using quantitative real-time PCR,
they evaluated 37 primary tumor samples for expression
of the four Notch receptors and two Notch target genes,Sarcoma 7
Hes1 and Hey1. They found increased expression of Notch2
a n dN o t c h 3i nb o t he R M Sa n da R M Sc o m p a r e dt oa d u l t
and fetal skeletal muscle. In addition, they found an increase
in Hes1 in eRMS and an increase in Hey1 in both eRMS
andaRMS.TheythenshowedthatNotchinhibition,through
both γ-secretase inhibitors and dominant negative MAML1
coactivator construct, decreases RMS cell line mobility and
invasiveness in vitro as measured by wound healing assays
and Matrigel/Transwell invasion assays, respectively.
Recently we have investigated the role of the Notch-Hey1
pathway inhibition in eRMS [20]. Inhibition of Notch sig-
naling via Notch1 shRNA, Hey1 shRNA, or γ-secretase inhi-
bitorsinvitroresultedindecreasedproliferationofeRMScell
lines, and reduction of the Notch target gene Hey1 resulted
in an increase in early diﬀerentiation. In murine eRMS xeno-
graft models, treatment with either Notch1 shRNA or γ-
secretase inhibitors inhibited tumor growth, providing pre-
clinical evidence of a role for Notch pathway inhibition in
eRMS. The role of Notch signaling in RMS stem cell mainte-
nancehasnotbeenspeciﬁcallyaddressed,althoughitappears
that Notch upregulation via constitutively active ICN1 en-
hances the formation of “rhabdospheres” (unpublished
data), a recently described source of eRMS cancer stem cells
that exhibits upregulated stem cell genes and increased
tumorigenicity[57].Furtherstudiesarenecessarytoevaluate
if pharmacologic Notch inhibition decreases the cancer stem
cell population of RMS.
3.2. Wnt and Rhabdomyosarcoma. The Wnt/β-catenin path-
way was ﬁrst identiﬁed as protumorigenic when an inactivat-
ing mutation in APC was described in human colon cancer
[58]. Since then, many human cancers have been shown to
harbor changes in the Wnt pathway, resulting in upregulated
β-catenin activity and target gene expression [32]. On the
other hand, inactivation of GSK3 (which activatesβ-catenin)
causes cell cycle arrest in leukemia [59], decreased cell prolif-
eration in pancreatic cancer [60], and apoptosis in colorectal
cancer [61]. Furthermore, the Wnt pathway inhibitor SFRP3
is upregulated in metastatic renal carcinoma [62]. Thus,
while the prevailing view had been that upregulation of the
Wnt/β-catenin pathway necessarily meant that it was tumor-
igenic, the role of Wnt pathway members such as GSK3 in
other signaling pathways and the cell or tissue context of the
Wnt pathway signals suggest that the role of Wnt signaling in
t u m o r i g e n e s i si sm o r ec o m p l e x .
Currently, very little is known about the role of Wnt in
RMS. In eRMS, the Wnt pathway was investigated using cells
derived from eRMS tumors formed in p53−/−/cfos−/− mice
and human eRMS cells (RD cells) [21]. These cells overex-
press Wnt2 but show downregulated β-catenin activity when
comparedtonormalmusclemyoblasts.ReactivatingtheWnt
pathway in eRMS cells induced MyoD expression and pro-
moted diﬀerentiation. This work suggests that inducing the
Wnt pathway could be a potential therapeutic approach for
treating eRMS. Also in a small set of samples from patients’
tumors, aRMS, eRMS, and sclerosing RMS (sRMS) all
show cytoplasmic localization of β-catenin, suggesting that
a downregulation of the Wnt pathway is a common feature
of RMS tumors; however this downregulation is not due to
am u t a t i o ni nβ-catenin [63]. This was also observed in a
diﬀerentsetofpatienttumorsamples,inwhichnoRMScon-
tained over 25% of cells staining positive for nuclear β-cate-
nin and only 15% of RMS contained any cells staining posi-
tive for nuclear β-catenin [64].
In aRMS, GSK3 inhibitors, which result in the activa-
tion of β-catenin, appeared to preferentially inhibit cell pro-
liferation and induce apoptosis when compared with eRMS
cells [22]. Further, GSK3 inhibitors appeared to reduce the
activity of the PAX3-FOXO1 protein, as PAX3-FOXO1 is
phosphorylated by GSK3. Previous work had demonstrated
that inhibiting PAX3-FOXO1 activity through the use of a
PAX3-KRAB does inhibit growth of aRMS cells in conditions
of low serum or soft agar and inhibits tumor xenograft for-
mation in immunodeﬁcient mice [65]. More work is re-
quired to understand if downregulation of the Wnt pathway
also inhibits diﬀerentiation in aRMS and sRMS tumors, as it
does in eRMS.
In conclusion, downregulation of the Wnt pathway ap-
pears to play an important role in RMS tumorigenesis. Thus,
activatingtheWntpathwayinRMStumorsmaybeapromis-
ing future strategy for the treatment of both aRMS and
eRMS.
3.3. Hedgehog and Rhabdomyosarcoma. Clinical evidence
supporting a role for Hedgehog signaling in RMS etiology
is well established. Individuals with germline mutations in
PTCH1(Gorlinsyndrome)aresusceptibletomultiplemalig-
nancies such as basal cell carcinoma (BCC), medulloblas-
toma, and to a lesser extent RMS [66]. In parallel, mice that
are heterozygous for Ptch1 demonstrate a phenotype similar
to patients with Gorlin syndrome [67]; however, diﬀerences
in mouse strain or background have a marked eﬀect on
susceptibility to RMS, which may explain the overall low fre-
quency of RMS in Gorlin syndrome patients, when com-
pared to BCC and medulloblastoma [68] .Th er o l eo fPTCH1
mutations in sporadic human RMS is less clear. Recent stud-
ies in human tumors that searched for mutations in either
PTCH1orSMOhaveyieldedconﬂictingresults.Forexample,
one study found that only one out of 14 RMS samples sequ-
ences demonstrated loss of heterozygosity (LOH) at the
PTCH1 locus and there were no point mutations or deletions
found in the RMS samples tested [69]. In contrast, another
group demonstrated that four out of 12 RMS tumors exhib-
ited loss of 9q22 (containing PTCH1) ,s u g g e s t i n gt h a ti tm a y
play a role in sporadic RMS [70]. In addition, a recent study
found that 12 out of 34 fetal rhabdomyomas and eRMS
lacked PTCH1 immunoreactivity and four of nine tumors
examined had LOH at the PTCH1 locus [71].
Because eRMS is one of the three major tumor types that
develop in Ptch1+/− mutant mice [72] and the other two
tumor types (BCC and medulloblastoma) have shown res-
ponse to SMO inhibition in vivo [73], it was assumed that
targeting the Hedgehog pathway would have utility in eRMS.
However, such an approach has proven challenging because
even though Ptch1+/− mouse tumors depend on Smo for
RMS initiation, the SMO inhibitor cyclopamine does not8 Sarcoma
Table 2: Clinical trials evaluating drugs that target Notch, WNT, or Hedgehog signaling pathways in children.
ClinicalTrials.gov
no. Indication Compound Mechanism Phase Start date Completion
date
Sponsor/
collaborator
Notch
NCT00100152 Relapsed/refractory T cell
ALL/lymphoma MK0752 Gamma-secretase
inhibitor I Jul 2005 Oct 2006 Merck
NCT01088763
Relapsed/refractory solid
tumors, CNS tumors,
lymphoma, T cell leukemia
RO4929097 Gamma-secretase
inhibitor I/II Mar 2010 May 2011
Children’s
Oncology
Group/NCI
NCT01236586
Relapsed/refractory solid
tumors, CNS tumors,
lymphoma, T cell leukemia
RO4929097 Gamma-secretase
inhibitor I/II Oct 2010 Apr 2011 NCI/NIH CC
WNT
Hedgehog
NCT00822458 Recurrent/refractory
medulloblastoma GDC-0049
Smo
small-molecule
inhibitor
I Jan 2009 Jul 2011
Pediatric brain
tumor
consortium/NCI
NCT01239316 Recurrent/refractory
medulloblastoma GDC-0449
Smo
small-molecule
inhibitor
II Nov 2010 Ongoing
Pediatric brain
tumor
consortium/NCI
NCT01125800
Medulloblastoma,
rhabdomyosarcoma,
neuroblastoma,
hepatoblastoma, high-grade
glioma, astrocytoma
LDE225
Smo
small-molecule
inhibitor
I Feb 2011 Ongoing Novartis
Pharmaceuticals
Obtained from clinicaltrials.gov website January 8, 2012.
appear to suppress tumor growth in vivo [74]. Studies with
human eRMS cell lines also failed to respond to cyclopamine
in vitro and in vivo. However, Hedgehog signaling was still
implicated in these same RMS cell lines because they res-
ponded to a novel GLI antagonist GANT 61 (Gli Antagonist
61) [23]. In addition, Gerber et al. demonstrated that over-
expressionofGli1inhibiteddiﬀerentiationofmyogenicRMS
cell lines [24]. In these studies, they showed that Gli1 and
Gli2 repress the ability of MyoD to activate transcription and
drive myogenic diﬀerentiation. Finally, a recent study ob-
servedthatapproximately30%offusion-negativeRMSscon-
tain an altered SHH pathway signature, consistent with acti-
vation of the pathway [75].
IncontrasttoeRMS,theHedgehogpathwayisnotknown
to play a signiﬁcant role in aRMS. In fact, recent studies on
human tissue samples demonstrated not only that aRMS
tumors had reduced levels of GLI1 transcript but that aRMS
samplesthatharboredthe12q13-15ampliconcontainingthe
GLI1 gene did not lead to increased protein expression [76].
4. DrugsThat Target the Notch, Wnt, and
Hedgehog Embryonic Pathways
As discussed above, defects in the embryonic signaling path-
ways that control muscle development may underlie some
of the aberrant proliferation and arrested diﬀerentiation in
RMS. Developmental programs responsible for controlling
self-renewal and diﬀerentiation in muscle progenitor cells,
including Notch, WNT, and Hedgehog, may contribute to
RMS tumorigenesis and are therefore attractive pathways
for therapeutic targeting. Currently, several drugs targeting
the Notch, WNT, or Hedgehog pathways are in pediatric
(Table 2) and/or sarcoma (Table 3) clinical trials. Options
for pharmacologic targeting of the Notch pathway include
γ-secretase inhibitors, which block the proteolytic cleavage
and subsequentactivation of theNotch receptors[77].While
these drugs have been evaluated in clinical phase I and
II trials, their side eﬀect proﬁle, including gastrointestinal
toxicities, currently precludes broader evaluation. Further,
this enzyme complex targets other substrates in addition to
Notch receptor as evidenced by their initial development
for treatment of Alzheimer’s disease [78]. More direct inhi-
bition of the Notch transcription factor complex, without
the attendant gastrointestinal toxicity, has been achieved
using hydrocarbon-stapled peptides, but this pharmacologic
approach is still early in its preclinical development [79].
Regarding the Wnt pathway, most drugs being developed
as cancer therapeutics are aimed at inhibiting the pathway
[80, 81] since as described above when Wnt signaling is mu-
tated in human cancer it is usually upregulated. These inhi-
bitors appear to work at diﬀerent levels of the Wnt pathway;
for example, XAV939 inhibits Axin, while iCRT-3, 5, and 14
inhibit the β-catenin-TCF interaction [82, 83]. Recently, a
phase I trial evaluating a chimeric humanized monoclonal
antibody against FZD10 (Frizzled Family Receptor 10) has
opened for patients with synovial sarcoma (Table 3), so that
inhibiting the Wnt pathway at the level of a Frizzled receptor
might also become a possibility. For RMS, current evidence
suggests that one would need to activate the Wnt pathway.
Such drugs include lithium chloride and lithium salts, whichSarcoma 9
Table 3: Clinical trials evaluating drugs that target Notch, WNT, or Hedgehog signaling pathways in sarcomas.
ClinicalTrials.gov
no. Indication Compound Mechanism Phase Start date Completion
date
Sponsor/
collaborator
Notch
NCT01154452 Advanced or metastatic
sarcoma RO4929097 Gamma-secretase
inhibitor I/II Jun 2010 Nov 2010
Memorial Sloan
Kettering Cancer
Center/NCI
NCT01236586
Relapsed/refractory solid
tumors, CNS tumors,
lymphoma, T-cell
leukemia
RO4929097 Gamma-secretase
inhibitor I/II Oct 2010 Apr 2011 NCI/NIH CC
WNT
NCT01469975 Synovial sarcoma OTSA101
Chimeric
humanized
monoclonal
antibody against
FZD10
I Dec 2011 Dec 2013
Centre Leon
Berard/OncoTherapy
Science, Inc.
Hedgehog
NCT01154452 Advanced or metastatic
sarcoma GDC-0449
Smo
small-molecule
inhibitor
I/II Jun 2010 Nov 2010
Memorial Sloan
Kettering Cancer
Center/NCI
NCT01267955 Advanced
chondrosarcoma GDC-0449
Smo
small-molecule
inhibitor
II Dec 2010 Feb 2012 Institut Bergoni´ e/NCI
NCT01310816 Metastatic or unresectable
chondrosarcoma IPI-296
Smo
small-molecule
inhibitor
II Feb 2011 Sep 2015 Inﬁnity
Pharmaceuticals, Inc.
NCT01125800
Medulloblastoma,
rhabdomyosarcoma,
neuroblastoma,
hepatoblastoma,
high-grade glioma,
astrocytoma
LDE225
Smo
small-molecule
inhibitor
I Feb 2011 Ongoing Novartis
Pharmaceuticals
Obtained from clinicaltrials.gov website January 8, 2012.
are known to activate the Wnt pathway through inhibition
of GSK3 [84]. Underscoring the relative safety record of
lithium salts, they are used to treat bipolar disorder not only
in adulthood but during older childhood and adolescence
[85], and even during pregnancy, with limited risk to the
fetus despite equilibration across the placenta [86, 87].
Lithium chloride was also studied in adult patients with low-
grade neuroendocrine tumors (NET), as GSK3β regulates
growth and hormone production in NETs; however, it was
ineﬀective at inhibiting NET growth [88]. In recent years,
other drugs that activate the Wnt pathway have been devel-
oped. Maleimide derivatives SB216763 and SB415286 and
indirubin analogs BIO and INO all selectively inhibit GSK3
[89, 90]. WAY-316606, a small-molecule inhibitor of SFRP1,
was shown to stimulate bone formation in an in vitro model
of osteoporosis [91].
Although cyclopamine does not appear to be eﬀective for
Ptch1-mutant RMS, it is possible that pharmacologic block-
ade of the Hedgehog pathway with other drugs will be a
usefulapproachfortreatingthesetumors.Forexample,other
drugs that inhibit SMO have recently been developed inclu-
ding SANT-1, SANT-2, and GDC-0449 [92, 93] and drugs
listed in Tables 2 and 3. Interestingly, a recent phase I
trial demonstrated that GDC-0449 caused a partial or com-
plete response in the majority of patients with BCC and
medulloblastoma [73]. Whether these or other drugs that
target other components of the Hedgehog pathway will be
eﬀective in treating RMS remains to be established.
In summary, there is enough evidence supporting a link
between the Notch, Wnt, and Hedgehog embryonic path-
ways and RMS tumorigenesis to continue evaluating the
blockade of these pathways in preclinical studies. But the
optimism of these observations must be balanced by the
feasibility of targeting these pathways in children. Therapies
designed to target aberrant stem cell pathways involved in
tumor development may also unwittingly inhibit normal,
essential stem cell pathways required for normal growth and
development into adulthood, a deﬁning characteristic of the
pediatric population.
5. Discussion
Embryonic cancers such as RMS are believed to result at least
in part from defective developmental processes. As such, the10 Sarcoma
genes and signaling pathways responsible for normal regu-
lation of myogenic proliferation and diﬀerentiation remain
vulnerable for transformation and may act as potential RMS
oncogenes. It has been hypothesized that RMS may arise
from muscle stem cells or, alternatively, diﬀerentiated muscle
cells may undergo mutations that stimulate dediﬀerentiation
and reactivate self-renewal. Regardless of the precise cell of
origin, mutations in embryonic signaling pathways may
function as primary events in tumorigenesis, or secondary,
cooperating mutations. An improved understanding of the
rolesofembryonicsignalingpathwaysinRMStumorigenesis
will allow for the identiﬁcation of critical targets and pro-
mote the development of rational therapies.
The Notch, WNT, and Hedgehog pathways are regulators
of myogenic lineage determination and maturation, and, ac-
cordingly,RMSmayarisefromdisorderedregulationofthese
normaldevelopmentalpathways.Inthispaper,wehavesum-
marized the known role of these signaling pathways during
myogenesis and the current data supporting a link to rhab-
domyosarcomagenesis. In summary, these embryonic sig-
naling pathways are responsible for controlling the balance
between undiﬀerentiated muscle progenitor cells and non-
proliferative diﬀerentiated myotubes. By favoring self-rene-
w a lv e r s u sad i ﬀerentiated phenotype, muscle stem cells are
at an increased risk for accumulating mutations necessary
for oncogenesis; this is more likely to occur in cells that self-
renew and do not exit the cell cycle or undergo apoptosis.
Rational drug targets are being identiﬁed and employed
in RMS clinical trials (IGF1R inhibition, antiangiogenic ap-
proaches, and mTOR inhibition). However, progress has
been slow for a variety of reasons. First, despite being the
mostcommonsofttissuesarcomainchildhood,RMSisstilla
rare disease. Therefore, there are relatively few patients avai-
lable to enroll on early phase trials, and there are an increas-
ing number of novel therapies with promising preclinical
data competing for patient accrual. Second, many patients
who are eligible for phase I studies do not choose to parti-
cipate due to a history of heavy pretreatment and a general
sense of “hopelessness” associated with “toxicity trials.” One
strategytoovercomebothoftheseobstaclesistoopenphaseI
trials of targeted therapeutics to patients who achieve remis-
sion but remain at high risk for disease relapse. This appro-
ach of investigating novel therapeutics as “maintenance ther-
apy” would increase the number of patients available for
enrollment in phase I trials and would also likely result in
a higher accrual rate. A population of patients in remission
wouldbehealthierthanpatientswithrelapse,andtheymight
be more likely to perceive hope with novel, single-agent ther-
apies aimed at maintaining a ﬁrst remission as opposed to
inducing a second remission. In support of this approach,
the most recent European Cooperative Sarcoma Group trial,
CWS-96, demonstrated an improved survival for patients
withmetastaticsofttissuesarcomastreatedwithoralmainte-
nance therapies compared to high-dose chemotherapy with
a ﬁve-year overall survival of 52% versus 15%, respectively,
[94]. While this study was a nonrandomized design and
had relatively small numbers, the treatment groups had
similar characteristics, and the diﬀerences were statistically
signiﬁcant suggesting that maintenance regimens are feasible
and a promising strategy for the treatment of high risk
RMS.
Based on the data presented in this paper, we conclude
that the Notch, Wnt, and Hedgehog embryonic signaling
pathways are important in RMS for the transformation of
precursorcells,initiationoftumors,andmaintenanceofself-
renewal properties. Given the persistently dismal cure rates
for patients with high-risk RMS,animproved understanding
of the role of these pathways in RMS may provide an op-
portunity to pharmacologically target these embryonic path-
ways and improve survival of patients with RMS.
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